Gilead Sciences Inc Common Stock(GILD)

Trading Analysis Report: GILD

• Analysis date: 2026-05-29
• Processed decision: Buy
• Price Target: $160

I. Analyst Team Reports

Market Analyst

Investment Snapshot

Gilead closed at $134.43 on May 29, 2026, near its 50-day average and above its 200-day average. The stock is below the $157.29 52-week high and below the $160 median analyst target, leaving a reasonable upside path if core HIV growth and pipeline progress remain intact.

The latest fundamentals support a Buy rating. Q1 2026 total revenue was $6.960 billion, up 4%, while product sales excluding Veklury were $6.802 billion, up 8%. HIV product sales increased 10% to $5.030 billion, led by Biktarvy and Descovy. Gilead also raised 2026 product sales guidance to $30.0 billion to $30.4 billion.

Valuation is moderate. Forward P/E is 14.02x, EV/EBITDA is 12.16x, and the dividend yield is 2.44%. The $160 target is anchored to the analyst median target and implies about 19% upside from the May 29 close.

Sources: Gilead Q1 2026 earnings release dated May 7, 2026; Gilead FY2025 earnings release dated February 10, 2026; market snapshot retrieved May 31, 2026 for the May 29, 2026 NASDAQ close.

Sentiment Analyst

Sentiment View

Sentiment is constructive. The market snapshot shows a Buy recommendation key across 29 analyst opinions, with a $157.83 mean target and a $160.00 median target. That target support matters because Gilead is a defensive, cash-generative stock with a dividend and a visible HIV franchise.

The Q1 2026 narrative was positive for the base business. Product sales excluding Veklury grew 8%, HIV grew 10%, Biktarvy grew 7%, Descovy grew 38%, and Trodelvy grew 37%. These growth rates show that Gilead is not only relying on mature HIV cash flows.

The sentiment risk is EPS noise from business development. Management reduced GAAP and non-GAAP EPS guidance by about $9.50 because of anticipated acquired IPR&D charges and financing costs from the Arcellx, Ouro, and Tubulis transactions. Investors may tolerate that if pipeline value improves, but near-term earnings optics are messy.

News Analyst

News and Catalyst View

The May 7, 2026 Q1 release is the main catalyst. Gilead reported total revenue of $6.960 billion, product sales of $6.946 billion, diluted EPS of $1.61, non-GAAP diluted EPS of $2.03, and operating cash flow of $2.5 billion.

Product details were encouraging. HIV product sales were $5.030 billion, up 10%, Biktarvy sales were $3.4 billion, up 7%, Descovy sales were $807 million, up 38%, and Trodelvy sales were $402 million, up 37%. Veklury sales fell 52% to $144 million, but the base business excluding Veklury grew 8%.

Guidance was mixed but strategically understandable. Product sales guidance was raised to $30.0 billion to $30.4 billion, and product sales excluding Veklury guidance was raised to $29.4 billion to $29.8 billion. However, GAAP and non-GAAP EPS guidance was reduced by about $9.50 because of expected acquired IPR&D charges and financing costs related to Arcellx, Ouro, and Tubulis.

Key future catalysts include lenacapavir HIV prevention execution, oncology and cell therapy progress, Trodelvy momentum, and integration of the newly acquired pipeline assets. Downside catalysts include clinical failures, reimbursement pressure, HIV competition, and acquisition-related dilution.

Fundamentals Analyst

Fundamentals View

Gilead's fundamentals are solid. Q1 2026 total revenue grew 4% to $6.960 billion, product sales excluding Veklury grew 8% to $6.802 billion, and operating cash flow was $2.5 billion. Non-GAAP diluted EPS was $2.03 despite transaction-related and pipeline-investment noise.

The HIV franchise remains the core. HIV product sales were $5.030 billion, up 10%, with Biktarvy at $3.4 billion, up 7%, and Descovy at $807 million, up 38%. This cash engine funds the dividend, research, oncology investment, and business development.

Growth is not risk-free. Cell therapy product sales declined 12% to $407 million, and Veklury declined 52% to $144 million. Gilead needs oncology, cell therapy, and prevention assets to expand beyond the mature HIV base over time.

The FY2025 base was strong enough to support the thesis. FY2025 total revenue was $29.4 billion, product sales excluding Veklury were $28.0 billion, HIV product sales were $20.8 billion, Biktarvy sales were $14.3 billion, and non-GAAP diluted EPS was $8.15. The market snapshot also shows $10.81 billion of operating cash flow and a 2.44% dividend yield.

II. Research Team Decision

Bull Researcher

Bull Case

The bull case is that Gilead combines defensive cash flow with underappreciated pipeline optionality. HIV sales are still growing double digits, product sales excluding Veklury are growing, and operating cash flow remains substantial. The stock trades at only about 14x forward earnings while offering a 2.44% dividend yield.

The pipeline and business-development strategy add upside. Arcellx, Ouro, and Tubulis are costly in the near term because of IPR&D charges, but they can deepen Gilead's oncology and immunology opportunities. Trodelvy's 37% growth also shows the oncology portfolio still has momentum.

A move to the $160 target is reasonable because it matches the median analyst target and does not require an aggressive valuation. It requires steady HIV growth, pipeline confidence, and less concern about one-time transaction charges.

Bear Researcher

Bear Case

The bear case is that Gilead's near-term EPS profile is noisy and pipeline execution risk is high. The reduction in 2026 EPS guidance by about $9.50 because of acquired IPR&D charges and financing costs can make reported results hard to interpret and may weigh on sentiment.

The business also faces concentration risk. HIV is strong, but it is a mature franchise exposed to pricing, competition, patent cycles, and treatment/prevention shifts. If HIV growth slows before oncology and newer pipeline assets scale, the stock may deserve only a moderate multiple.

Cell therapy weakness is another caution point. Q1 cell therapy product sales declined 12%, showing that not all growth areas are working. Acquisitions can help, but integration and clinical execution remain uncertain.

Research Manager

Research Manager Decision

The balanced decision is Buy. Gilead has a resilient HIV franchise, improving base-business sales excluding Veklury, substantial cash generation, a dividend, and pipeline optionality from oncology, cell therapy, and recent business-development deals.

Price Target: $160

The $160 target aligns with the analyst median target and implies roughly 19% upside from the $134.43 May 29 close. The target is supported by 8% product sales growth excluding Veklury, 10% HIV growth, raised product sales guidance, and moderate valuation. The rating would move to Hold if HIV growth slows materially, pipeline execution disappoints, or IPR&D and acquisition financing costs fail to translate into credible long-term growth.

III. Trading Team Plan

Trader

Trading Plan

Rating: Buy
Price Target: $160
Time Horizon: 6-12 months

Investment Snapshot

The trading plan is to accumulate Gilead while it trades near the 50-day average and below the $160 median target. The stock is above the 200-day average, so the longer-term trend remains constructive, while the dividend yield and cash flow support patience.

The first upside checkpoint is a recovery toward the $157.29 52-week high, followed by the $160 target. A stronger move toward the analyst high target would require clearer pipeline progress and reduced concern about transaction-related EPS dilution.

Risk controls should focus on HIV growth, Biktarvy and Descovy trends, Trodelvy momentum, cell therapy sales, 2026 product sales guidance, and acquired IPR&D charges. If product sales guidance is cut or HIV growth weakens, reassess the Buy.

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Risk View

The aggressive view supports buying now. Gilead's core business is stronger than the EPS guidance reset suggests: product sales excluding Veklury grew 8%, HIV grew 10%, Trodelvy grew 37%, and operating cash flow was $2.5 billion in Q1.

The aggressive case is that investors are over-penalizing acquired IPR&D charges. If Arcellx, Ouro, and Tubulis strengthen the long-term pipeline, the current valuation can look too low for a company with strong cash flow and dividend support.

Conservative Analyst

Conservative Risk View

The conservative view accepts Buy but emphasizes pipeline and transaction risk. Gilead has a high-quality cash engine, but a large portion of the future upside depends on clinical execution and business-development returns. EPS volatility from IPR&D charges can also make near-term valuation harder to interpret.

A conservative investor should stage entries and watch whether the raised product sales guidance is maintained. The dividend helps, but it does not eliminate pipeline risk.

Neutral Analyst

Neutral Risk View

The neutral view is Buy with measured sizing. The stock has reasonable upside to the $160 target, moderate valuation, and solid cash generation. The offset is that HIV remains the core profit pool while oncology, cell therapy, and acquired assets still need to prove durable growth.

Key metrics are product sales excluding Veklury, HIV sales, Biktarvy, Descovy, Trodelvy, cell therapy, operating cash flow, and progress on transaction-related pipeline assets.

V. Portfolio Manager Decision

Portfolio Manager

Portfolio Manager Decision

Final Rating: Buy
Price Target: $160

Investment Snapshot

Gilead should be rated Buy with a $160 target. Q1 2026 total revenue rose 4% to $6.960 billion, product sales excluding Veklury rose 8% to $6.802 billion, HIV product sales rose 10% to $5.030 billion, non-GAAP diluted EPS was $2.03, and operating cash flow was $2.5 billion. Management also raised 2026 product sales guidance.

The portfolio case is based on durable HIV cash flow, improving base-business growth, Trodelvy momentum, a 2.44% dividend yield, and pipeline optionality from recent transactions. Valuation is reasonable at about 14x forward earnings, and the $160 target matches the median analyst target.

The risk is that IPR&D charges, acquisition financing costs, cell therapy weakness, HIV competition, and clinical execution can create volatility. Maintain the Buy while HIV growth, base product sales, cash flow, and pipeline progress remain intact; downgrade to Hold if transaction costs do not convert into credible long-term growth.